Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs

Airò, Paolo; Antonioli, Chiara M.; Vianelli, M.; Toniati, Paola

doi:10.1093/rheumatology/41.3.347

Cited by 67 publications

(33 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Classical disease therapy relies on a high dose of GC administration once the clinical finding is suggestive of the disease [25,26]. Relapse is common in 60-70% of patients thus, other therapeutic modalities are required [23,27,28]. A meta-analysis in 2014 [29], included five studies about anti TNF alpha agents in GCA.…”

Section: Giant Cell Arteritismentioning

confidence: 99%

Use of Anti TNF-α Therapy in Systemic Vasculitis

Almteri¹,

Alshaiki²,

Hafiz³

et al. 2017

J Vasc

View full text Add to dashboard Cite

There are several vascultic disorders still labeled as difficult-to-treat cases. Effective treatment for those patients is warranted to reduce the mortality and morbidity that resulting from these disorders. An extensive review for the literatures that addressed using of ant TNF-alpha in several vascultic disorders was conducted. Use of anti TNFalpha agents is a promising modality in several vascultic disorders. Despite lacking well-conducted randomized controlled trials, more open-label studies are required to examine in-depth the safety and efficacy of those agents.

show abstract

Section: Giant Cell Arteritismentioning

confidence: 99%

Use of Anti TNF-α Therapy in Systemic Vasculitis

Almteri¹,

Alshaiki²,

Hafiz³

et al. 2017

J Vasc

View full text Add to dashboard Cite

show abstract

“…20 Additional case reports have suggested that TNFa inhibition may play a therapeutic role in GCA. [21][22][23] However, a randomised controlled trial comparing infliximab with placebo in 44 newly diagnosed GCA patients on a tapering dose of glucocorticoids showed contrasting results. Infliximab therapy, compared with placebo, did not increase the proportion of patients who were relapse-free at week 22 (0.43 versus 0.50; p = 0.65).…”

Section: Biologic Therapymentioning

confidence: 99%

Biologic Therapy for the Treatment of Giant Cell Arteritis

Ostrowski¹,

Bussey²,

Tehrani³

et al. 2014

Neuro-Ophthalmology

View full text Add to dashboard Cite

Giant cell arteritis (GCA), a vasculitis of the medium and large arteries, is traditionally managed with glucocorticoids. However, the side effects of chronic glucocorticoid use and the occurrence of refractory cases warrant the consideration of steroid-sparing agents, including biologic agents. Interleukin-6 (IL-6) inhibition shows the most promise as biologic therapy for refractory cases of GCA, but data to support the use of other existing biologic agents are currently lacking. A better understanding of the pathogenesis of GCA as well as clinical trials investigating both existing and emerging biologic agents is needed to expand therapeutic options for the treatment of GCA.

show abstract

“…Small series or case reports have suggested the possible utility of TNF-alpha inhibitors in treating patients with refractory or corticosteroid-dependent giant cell arteritis (GCA), including infliximab [71][72][73], etanercept [74] and adalimumab [75]. However, these data have not been confirmed in two controlled studies evaluating infliximab and etanercept.…”

Section: Giant Cell Arteritismentioning

confidence: 99%

Biologics and the Cardiovascular System: A Double-Edged Sword

Roubille

Martel‐Pelletier²,

Tardif³

et al. 2013

AIAAMC

View full text Add to dashboard Cite

Abstract:Patients with chronic inflammatory diseases such as rheumatoid arthritis have a higher risk of cardiovascular diseases and related mortality compared to the general population. This risk is first due to classical cardiovascular risk factors but also due to systemic inflammation which is independently involved, causing accelerated atherosclerosis, myocardial infarction, cerebrovascular disease and heart failure (HF). Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 and IL-6 could be major actors on this pathophysiology. Biologics are effective specific treatments in the management of inflammatory rheumatic and systemic diseases. In this review, beneficial and deleterious effects on the heart and vessels of the biologics used in the management of inflammatory arthritis and vasculitides will be discussed, focusing on TNF-alpha, IL-6 and IL-1 blockades, and anti-CD20. Noninflammatory cardiac conditions, such as heart failure, myocardial infarction, and cardiovascular conditions such as atherosclerosis, as well as inflammatory diseases including vasculitides will be discussed.

show abstract

Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs

Cited by 67 publications

References 8 publications

Use of Anti TNF-α Therapy in Systemic Vasculitis

Use of Anti TNF-α Therapy in Systemic Vasculitis

Biologic Therapy for the Treatment of Giant Cell Arteritis

Biologics and the Cardiovascular System: A Double-Edged Sword

Contact Info

Product

Resources

About